Comparing TMS Targeting Methods for Depression Treatment
This study is investigating whether using a mixed reality neuronavigation system (a device that helps guide treatment) to target the brain during Transcranial Magnetic Stimulation (TMS) treatment for depression can improve outcomes. TMS is a brain stimulation treatment for medication-resistant depression. We are comparing this new targeting method to traditional scalp measurements and another commercial neuronavigation system. The study aims to enroll 60 participants, aged 18 to 75, who are eligible for MRI scans. We will measure how many participants respond to TMS treatment after 9 weeks. The current recruitment status is unclear.
- Study design
- This interventional study plans to enroll 60 participants. It compares three groups receiving different TMS targeting methods.
- What's involved
- You would receive 30 daily weekday TMS treatments over 6 weeks, followed by 6 tapered treatments over 3 weeks. You would also need to be eligible for MRI scanning.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome, response to TMS, is measured at 9 weeks after treatment begins.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Comparison of Targeting Methods for Transcranial Magnetic Stimulation Treatment of Depression
At a glance
Conditions
NCT04730180
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Stanford University
Stanford, Californiastudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Jennifer A McNab, PhD · PRINCIPAL_INVESTIGATOR · Stanford University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of participants with response to TMS9 weeks
We will count how many participants responded to TMS treatment in each arm. Response is measured as a more than 50% reduction in MADRS score per patient.